Gene Therapy for Wiskott-Aldrich Syndrome (TIGET-WAS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01515462|
Recruitment Status : Active, not recruiting
First Posted : January 24, 2012
Last Update Posted : February 25, 2021
|Condition or disease||Intervention/treatment||Phase|
|Wiskott-Aldrich Syndrome (WAS)||Genetic: OTL-103||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||8 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||This will be a single-arm study. All subjects will receive OTL-103 gene therapy and will be followed up for 8 years post gene therapy|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome|
|Actual Study Start Date :||April 20, 2010|
|Actual Primary Completion Date :||October 3, 2018|
|Estimated Study Completion Date :||September 11, 2025|
Experimental: OTL-103 gene therapy
Eligible subjects will receive intravenous (IV) infusion of OTL-103 gene therapy. Subjects affected by WAS who don't have a suitable matched donor for allogenic hematopoietic stem cell transplantation will be included
OTL-103 is an autologous CD34+ cells collected from bone marrow and/or peripheral blood and transduced with a lentiviral vector encoding Wiskott-Aldrich syndrome (WAS) protein
Other Name: Previously GSK2696275
- Conditioning regimen-related safety [ Time Frame: Two months after gene therapy ]Absence of engraftment failure or prolonged aplasia (<500/ul ANC with no evidence of bone marrow recovery) and surveillance of non haematological regimen related toxicity (for clinical features NCI >2, for metabolic/laboratory NCI >3)
- Safety of lentivirus gene transfer into HSC [ Time Frame: 3 years ]Short-term safety and tolerability of lentiviral-transduced cell infusion-long-term safety of lentiviral-transduced cell infusion (absence of Replication Competent Lentivirus (RCL) and abnormal clonal proliferation).
- Sustained engraftment of genetically corrected haematopoietic stem cells in peripheral blood and/or in bone marrow [ Time Frame: 1 year ]≥ 0.04 Vector copy number (VCN)/cell in bone marrow CD34+ or ≥0.1 VCN/cell in peripheral blood T lymphocytes
- Expression of vector-derived WASP [ Time Frame: 1 year ]Detection of vector-derived WASP expression by FACS analyses and/or Western Blot
- Improved T-cell functions [ Time Frame: 3 years ]Improvement in in vitro T cell proliferation and/or IL-2 secretion upon stimulation with anti-CD3i as compared to pre-gene therapy values.
- Antigen-specific responses to vaccination [ Time Frame: >1year ]Ability to mount a humoral response to nominal antigens including antibodies to T cell dependent antigens (Tetanus Toxoid) and unconjugated polysaccharide antigens (Peumococcus, Meningococcus), measured after vaccination (foreseen >1 year after gene therapy). Positive cellular response to Tetanus Toxoid after vaccination measured by in vitro proliferative response >1 year after gene therapy.
- Improved platelet count and MPV normalization [ Time Frame: 3 years ]Sustained increase in platelet count compared to baseline, analyzing the individual longitudinal profile
- Overall survival [ Time Frame: 3 years ]Number of patients alive all over the trial
- Lack of immune response to transgene [ Time Frame: 3 years ]Immunoblot analysis
- Reduced frequency of severe infections [ Time Frame: 3 years ]Decrease in number of severe infections as evaluated in the second and third year after the treatment by clinical history, complete physical examinations, hematological and microbiological tests.
- Reduced bruising and bleeding episodes [ Time Frame: 3 years ]Reduction in bruising and/or bleeding manifestations when present, as assessed by clinical monitoring, compared to clinical history
- Reduced autoimmunity phenomena and eczema [ Time Frame: 3 years ]Reduction in laboratory markers (number and titer of antibody when available) and/or clinical manifestations of autoimmunity, as evaluated by organ-specific and systemic autoantibodies, imaging and clinical follow-up, compared to clinical history. Reduction in eczema as evaluated by clinical score
- Improved quality of life [ Time Frame: 3 year ]Improved quality of life, measured after the first year of treatment by reduced hospitalization, reduced requirement of drugs, school attendance, social activities.
- Multilineage engraftment of genetically corrected cells [ Time Frame: 3 years ]≥0.04 VCN/cell on all the available peripheral blood and/or bone marrow cell subpopulations (BM subpopulations: GlyA+, CD15+, CD61+, CD3+, CD19+, CD56+; PB subpopulations: CD15+, CD19+, CD56+)
- Overall safety of the treatment [ Time Frame: 8 years ]Recording of AE, AR, SAE/SAR, UAR, SUSAR
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01515462
|Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET)|
|Milan, Italy, 20132|
|Study Director:||Orchard Clinical Trials||Orchard Therapeutics|